RGB-19 Phase I Clinical Study
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Registration Number
- JPRN-jRCT2031230029
- Lead Sponsor
- Watanabe Manabu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 110
Inclusion Criteria
Male volunteers who voluntarily wish to participate in the study, have the capacity to provide consent, and have provided written informed consent to participate in the study.
Volunteers from 20 to 40 years of age (both inclusive) when signing informed consent.
Exclusion Criteria
Volunteers previously exposed to tocilizumab, any other IL-6 inhibitors, or IL-6 receptor inhibitors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Maximum serum drug concentration (Cmax)<br>AUC from 0 hours (immediately before administration) to infinity (AUCinf)
- Secondary Outcome Measures
Name Time Method